Q-Bank Breakdown: Bioavailability — Why Every Answer Choice Matters

You’ve probably seen this in a Q-bank: the stem looks like it’s about dosing, the options look like they’re about absorption, and suddenly you’re second-guessing whether the question is secretly about first-pass metabolism or protein binding. Bioavailability questions are classic because the correct answer is usually simple, but the distractors are all nearby concepts that USMLE expects you to differentiate fast.

Tag: Pharmacology > General Principles

---

The Clinical Vignette (Q-Bank Style)

A 58-year-old man with atrial fibrillation is started on an oral anticoagulant. One week later, his dose is increased because his plasma drug levels remain lower than expected. He denies missing doses. He recently began taking an over-the-counter medication for heartburn. The clinician suspects the patient’s bioavailability of the anticoagulant has decreased.

Which of the following best describes bioavailability?

A. Fraction of drug that is ionized at physiologic pH
B. Fraction of drug bound to plasma proteins
C. Fraction of administered drug that reaches the systemic circulation unchanged
D. Rate at which a drug is eliminated by the kidney
E. Apparent volume in which a drug is distributed

---

Correct Answer: C — Fraction of administered drug that reaches systemic circulation unchanged

What bioavailability (F) actually is

Bioavailability (F) is the fraction of an administered dose that reaches the systemic circulation in unchanged form.

• IV administration: by definition, $F = 1$ (100%)
• Oral (and other non-IV routes): $F < 1$ due to:
  • Incomplete absorption (drug never gets into portal blood)
  • First-pass metabolism (drug absorbed → metabolized in gut wall and/or liver before systemic circulation)

High-yield equation links

• Absolute bioavailability (compared to IV): $F = \frac{AUC_{po}}{AUC_{iv}} \times \frac{Dose_{iv}}{Dose_{po}}$

• AUC (Area Under the Curve) reflects total drug exposure and scales with:

  • bioavailability ($F$)
  • dose
  • clearance ($CL$)

A common relationship you’ll see conceptually: $AUC \propto \frac{F \times Dose}{CL}$

How the vignette hints at decreased F

The new OTC heartburn drug could be something that reduces absorption (e.g., changes gastric pH) or binds the drug in the GI tract. Either way: less drug reaches systemic circulation unchanged → lower plasma levels → “needs” higher dose.

---

Systematically Destroying the Distractors (Why Each One Matters)

USMLE loves answer choices that are true statements—just not the one being asked. Here’s how to separate them.

---

A. Fraction of drug that is ionized at physiologic pH ❌

This is about ionization, governed by pH and pKa, which influences membrane permeability (absorption/distribution), not the definition of bioavailability.

High-yield linkage

• Weak acids are more unionized (better absorbed) in acidic environments.
• Weak bases are more unionized in basic environments.

Use Henderson–Hasselbalch logic:

• Weak acid: $pH = pK_a + \log\left(\frac{A^-}{HA}\right)$
• Weak base: $pH = pK_a + \log\left(\frac{B}{BH^+}\right)$

Why it’s tempting: Ionization affects absorption, which affects F, but it’s not what F is.

---

B. Fraction of drug bound to plasma proteins ❌

This is about protein binding (mostly albumin for acidic drugs; $\alpha_1$-acid glycoprotein for basic drugs). Protein binding affects distribution and free (active) drug, not bioavailability.

High-yield facts

• Only free drug:
  • crosses membranes
  • binds receptors
  • is filtered by the kidney (though secretion and reabsorption complicate this)
• Highly protein-bound drugs can have drug–drug interactions via displacement (clinically variable importance—USMLE tests the concept more than real-world magnitude).

Why it’s tempting: A decrease in free fraction can lower effect, but plasma concentration and exposure patterns differ from changes in F.

---

D. Rate at which a drug is eliminated by the kidney ❌

This is about renal clearance—part of total clearance ($CL$). Clearance affects AUC, but it’s not bioavailability.

High-yield clarification

• Clearance (CL) = volume of plasma cleared of drug per unit time.
• Total clearance can include:
  • hepatic metabolism
  • renal excretion
  • other routes (bile, lungs, etc.)

Board-style trap:
If the question said “AUC decreased”, you must decide whether it’s due to ↓F or ↑CL. Here, the stem says bioavailability decreased, and the option is asking for the definition.

---

E. Apparent volume in which a drug is distributed ❌

This is volume of distribution (Vd), a pharmacokinetic parameter relating the amount of drug in the body to plasma concentration.

$V_d = \frac{\text{Amount of drug in body}}{C_p}$

High-yield Vd intuition

• High Vd: drug leaves plasma and distributes into tissues (lipophilic drugs, tissue binding)
• Low Vd: drug stays in plasma (hydrophilic drugs, large molecules, high protein binding)

Why it’s tempting: Students sometimes confuse “how much gets into the body” (bioavailability) with “where it goes once it’s in” (distribution).

---

Rapid-Fire: What Decreases vs Increases Bioavailability

Common reasons bioavailability decreases

• Reduced absorption
  • chelation/binding in gut (classic: tetracyclines + Ca/Fe; fluoroquinolones + antacids)
  • increased gastric pH affecting dissolution/absorption for certain drugs
  • diarrhea, malabsorption, bariatric surgery
• Increased first-pass metabolism
  • enzyme induction (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) → more hepatic metabolism before systemic circulation
• P-glycoprotein (MDR1) efflux in intestinal epithelium
  • pumps drug back into lumen → less net absorption

Common reasons bioavailability increases

• Reduced first-pass metabolism
  • liver disease (less functional metabolism)
  • enzyme inhibition (e.g., cimetidine; azoles; macrolides; grapefruit juice for some CYP3A4 substrates)
• Alternative routes
  • sublingual and transdermal can bypass (much of) first-pass metabolism
  • rectal administration partially bypasses portal circulation (upper rectum drains portal; lower rectum systemic—USMLE sometimes tests this nuance)

---

Bioavailability vs the Other “B” and “C” Terms (Quick Table)

---

How USMLE Tries to Trick You (And How to Stay Untricked)

Step 1 pattern

• They’ll ask definitions and simple consequences:
  • “Which parameter changes with first-pass metabolism?” → bioavailability
  • “IV vs PO AUC comparison” → compute or interpret F

Step 2 pattern

• They’ll embed it in clinical decision-making:
  • switching from IV to PO and adjusting dose
  • drug interactions decreasing absorption (antacids, bile acid resins)
  • hepatic disease changing first-pass metabolism

Test-day move:
When you see “bioavailability,” translate instantly to:

💡

“How much of the administered dose gets into systemic blood unchanged?”

Then treat every other choice as a different pharmacokinetic knob.

---

Takeaway: The One-Line Memory Hook

Bioavailability is “getting in.”
Everything else (protein binding, Vd, clearance, ionization) is about what happens after—or what influences getting in, but isn’t the definition.